Company Website

Contact Information:
David Mills
Phone: 703-447-8105
​​​​​david.mills@mirumpharma.com

Virtual Exhibit Hall Home
 

LIVMARLI is an ileal bile acid transporter (IBAT) inhibitor and the first approved treatment for cholestatic pruritus in patients with Alagille syndrome who are 3 months of age and older.

LIVMARLI interrupts recirculation of bile acids to the liver and increases fecal excretion of bile acids to decrease the bile acid pool in the body, with minimal systemic absorption.

During the first year of treatment, 84% (n=26/31) of patients with Alagille syndrome experienced clinically meaningful improvements in cholestatic pruritus compared with baseline with once-daily LIVMARLI.
-“Clinically meaningful” was defined as ≥1-point ItchRO(Obs) improvement vs baseline

Long-Term Liver Impact
In a post hoc analysis, patients with Alagille syndrome who were treated with LIVMARLI in 3 long-term clinical trials (N=76) were followed to identify predictors of long-term, transplant-free survival.

In the post hoc analysis, 93% of patients who achieved a >1-point reduction in ItchRO(Obs) (n=46) remained transplant free 6 years after starting LIVMARLI.

Backed by >5 years of safety data, LIVMARLI has a well-characterized safety and tolerability profile. The most common adverse reactions observed in clinical studies (n=86) were diarrhea, abdominal pain, vomiting, FSV deficiency, liver test abnormalities, GI bleeding, and bone fractures. For further details, please see Important Safety Information and full prescribing information at www.livmarlihcp.com.

* The impact of LIVMARLI treatment on transplant-free survival has not been established. No liver histology to assess hepatic fibrosis was collected.

Pruritus Finder Tool for Alagille Syndrome Patients